Mesoblast (MESO) completes patient treatment in pivotal Phase 3
Mesoblast (MESO) says it has achieved a major milestone by completing patient treatment in its pivotal Phase 3 trial for chronic low back pain.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.